Christine Furtek

3.1k total citations · 2 hit papers
21 papers, 2.3k citations indexed

About

Christine Furtek is a scholar working on Pharmacology, Physiology and Infectious Diseases. According to data from OpenAlex, Christine Furtek has authored 21 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Physiology and 4 papers in Infectious Diseases. Recurrent topics in Christine Furtek's work include Alzheimer's disease research and treatments (5 papers), Cholinesterase and Neurodegenerative Diseases (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Christine Furtek is often cited by papers focused on Alzheimer's disease research and treatments (5 papers), Cholinesterase and Neurodegenerative Diseases (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Christine Furtek collaborates with scholars based in United States, France and Belgium. Christine Furtek's co-authors include Man‐Wai Lo, James Kost, Michael Egan, Tiffini Voss, Pierre N. Tariot, Yuki Mukai, Bruno Vellas, Jeffrey L. Cummings, Robert Tipping and Coleen M. Clineschmidt and has published in prestigious journals such as New England Journal of Medicine, Neurology and The Journal of Pediatrics.

In The Last Decade

Christine Furtek

20 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

2018 471 citations Michael Egan, James Kost et al. New England Journal of Medicine profile →
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

2019 380 citations Michael Egan, James Kost et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Christine Furtek

Since Specialization

Citations

This map shows the geographic impact of Christine Furtek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Furtek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Furtek more than expected).

Fields of papers citing papers by Christine Furtek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine Furtek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Furtek. The network helps show where Christine Furtek may publish in the future.

Co-authorship network of co-authors of Christine Furtek

This figure shows the co-authorship network connecting the top 25 collaborators of Christine Furtek. A scholar is included among the top collaborators of Christine Furtek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Furtek. Christine Furtek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Progression from Prodromal Alzheimer’s Disease to Mild Alzheimer’s Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions 2023 ·Journal of Alzheimer s Disease ·Tiffini Voss, James Kost, (unknown), Christine Furtek, Christopher Randolph, Christopher Lines, Michael Egan, Jeffrey L. Cummings	3
2	A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials 2022 ·The AAPS Journal ·Marissa F. Dockendorf, (unknown), (unknown), Melanie Anderson, Sheila Breidinger, Lei Ma, (unknown), (unknown), Christopher J. Jones, Christine Furtek, Bhavna Kantesaria, Kevin P. Bateman, Eric Woolf, Michael Egan, Julie A. Stone	3
3	Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease 2020 ·Alzheimer s & Dementia ·Alette M. Wessels, Christopher Lines, Robert A. Stern, James Kost, Tiffini Voss, Lyn Harper Mozley, Christine Furtek, Yuki Mukai, Paul Aisen, (unknown), Pierre N. Tariot, Bruno Vellas, (unknown), Christopher Randolph, David Michelson, Scott W. Andersen, (unknown), John R. Sims, Michael Egan	59
4	Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease 2019 ·Alzheimer s Research & Therapy ·Michael Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie A. Stone, Christine Furtek, Erin Mahoney, Jeffrey L. Cummings, Pierre N. Tariot, Paul Aisen, Bruno Vellas, Christopher Lines, David Michelson	63
5	FTS3‐01‐05: FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE‐3 TRIAL OF VERUBECESTAT IN PRODROMAL AD 2019 ·Alzheimer s & Dementia ·Michael Egan, James Kost, Christopher Lines, Tiffini Voss, Lyn Harper Mozley, Christine Furtek, Yuki Mukai, Paul Aisen, Jeffrey L. Cummings, Pierre N. Tariot, Bruno Vellas, (unknown), Christopher Randolph, Cyrille Sur, David Michelson	0
6	Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease breakdown → 2019 ·New England Journal of Medicine ·Michael Egan, James Kost, Tiffini Voss, Yuki Mukai, Paul Aisen, Jeffrey L. Cummings, Pierre N. Tariot, Bruno Vellas, Christopher H. van Dyck, Merçé Boada, Ying Zhang, Wen Li, Christine Furtek, Erin Mahoney, Lyn Harper Mozley, Mo Yi, Cyrille Sur, David Michelson	380
7	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease breakdown → 2018 ·New England Journal of Medicine ·Michael Egan, James Kost, Pierre N. Tariot, Paul Aisen, Jeffrey L. Cummings, Bruno Vellas, Cyrille Sur, Yuki Mukai, Tiffini Voss, Christine Furtek, Erin Mahoney, Lyn Harper Mozley, Rik Vandenberghe, Mo Yi, David Michelson	471
8	Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine 2007 ·Neurology ·Tony W. Ho, (unknown), Xiaoyin Fan, C. Assaid, Christine Furtek, Christopher J. Jones, Christopher R. Lines, Alan M. Rapoport	367
9	Effect of Within-Household Reinfestation on Design Sensitivity 2003 ·Journal of Biopharmaceutical Statistics ·Cong Chen, A. Lawrence Gould, Robert Tipping, Cynthia Guzzo, Christine Furtek	1
10	Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects 2002 ·The Journal of Clinical Pharmacology ·Cynthia Guzzo, Christine Furtek, Arturo G. Porras, Cong Chen, Robert Tipping, Coleen M. Clineschmidt, David Sciberras, John Y.‐K. Hsieh, Kenneth C. Lasseter	215
11	Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects 2002 ·The Journal of Clinical Pharmacology ·Cynthia Guzzo, Christine Furtek, Arturo G. Porras, Cong Chen, Robert Tipping, Coleen M. Clineschmidt, David Sciberras, John Y‐K. Hsieh, Kenneth C. Lasseter	249
12	An observer-blinded study of 1% permethrin creme rinse with and without adjunctive combing in patients with head lice 2002 ·The Journal of Pediatrics ·Terri L. Meinking, Coleen M. Clineschmidt, Cong Chen, Michael A. Kolber, Robert Tipping, Christine Furtek, María Elena Villar, Cynthia Guzzo	41
13	Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19) 1999 ·European Journal of Clinical Pharmacology ·(unknown), Ming Lo, Bror Jonzon, P.A. Van Dalen, Christine Furtek, Markus Ritter, Gunnar Alván, Jacqueline B. McCrea, Folke Sjöqvist	9
14	Pharmacokinetics of Intravenous and Oral Losartan in Patients with Heart Failure 1998 ·The Journal of Clinical Pharmacology ·Man‐Wai Lo, (unknown), Scott E. Emmert, Michael Ritter, Christine Furtek, Hannah Lu, Wilson S. Colucci, Barry F. Uretsky, Ewa Rucinska	18
15	An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection 1997 ·Journal of Pharmaceutical and Biomedical Analysis ·Michael Ritter, Christine Furtek, Man‐Wai Lo	58
16	DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan* 1997 ·Clinical Pharmacology & Therapeutics ·Michael R. Goldberg, Man‐Wai Lo, David D. Christ, (unknown), Christine Furtek, Ohad Amit, Alexandra D. Carides, Jérôme Biollaz, Vincent Piguet, Juerg Nussberger, Hans R. Brunner	8
17	Ketoconazole does not effect the systemic conversion of losartan to E-3174. 1996 ·Clinical Pharmacology & Therapeutics ·Jacqueline B. McCrea, Ming Lo, Christine Furtek, Markus Ritter, (unknown), Scott A. Waldman, T D Bjornsson, Michael R. Goldberg	15
18	Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans 1995 ·Clinical Pharmacology & Therapeutics ·Man‐Wai Lo, Michael R. Goldberg, Jacqueline B. McCrea, Hannah Lu, Christine Furtek, Thorir D. Bjornsson	231
19	The pharmacokinetics of losartan in renal insufficiency 1995 ·Journal of Hypertension ·(unknown), Man‐Wai Lo, Wayne Shaw, William F. Keane, Todd W.B. Gehr, Charles E. Halstenson, (unknown), Christine Furtek, Michael Ritter, Shahnaz Shahinfar	44
20	Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography 1992 ·Journal of Chromatography B Biomedical Sciences and Applications ·Christine Furtek, Man‐Wai Lo	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact